rethinkTHC Search
Menu
Study breakdown

Cannflavin B, a non-psychoactive cannabis compound, improved social behavior and brain function in an autism rat model

Animal StudyPreliminary evidence
The takeaway

Cannflavin B, a non-psychoactive compound from cannabis, normalized social behavior, reduced anxiety-like behavior in females, and corrected brain wave abnormalities in adolescent rats exposed to prenatal valproic acid, a model used to study aspects of autism.

Autism researchers, cannabinoid pharmacologists, parents interested in cannabis-derived therapies

Cannflavin B normalized sociality in both sexes and corrected brain wave abnormalities in autism model rats

What the researchers found

Cannflavin B (0.2 mg/kg) was well tolerated and ameliorated most VPA-induced changes. It had anxiolytic-like properties in female VPA rats and normalized sociality in both sexes. Most VPA-induced brain wave abnormalities (spectral power, coherence, theta-gamma coupling) were corrected across prefrontal cortex, cingulate cortex, and hippocampus. Cannflavin B also reduced VPA-induced microglial activation in a sex- and region-specific manner.

Why it matters

No pharmacological treatments currently address the core symptoms of autism. While whole cannabis raises concerns for children and CBD results are inconsistent, cannflavin B offers a new non-psychoactive cannabis-derived compound worth investigating.

The numbers in context

0.2 mg/kg cannflavin B; brain regions assessed: prefrontal cortex, cingulate cortex, hippocampus; measures: oscillatory spectral power, coherence, theta-gamma cross-frequency synchrony, Iba1 microglial marker; sex-specific effects documented

How the study worked

Prenatal VPA exposure rat model of autism. Adolescent rats received cannflavin B (0.2 mg/kg, i.p.) and were assessed for behavioral outcomes (anxiety, sociality), neuronal oscillatory changes across brain regions, and microglial markers. Both in vivo and in vitro experiments were conducted.

What this study cannot tell us

Animal model of autism has limited translational relevance. Single dose tested. Prenatal VPA model captures some but not all aspects of autism. No human data exists for cannflavin B in autism or any neuropsychiatric condition.

How to read the evidence

Preliminary: animal study testing a novel compound in a single autism model. Well-designed with multiple outcomes but requires extensive validation.

When this study was published

2026 preclinical publication testing cannflavin B in adolescent rats.

The bigger picture

This highlights that cannabis contains many potentially therapeutic compounds beyond THC and CBD. Cannflavin B belongs to a class of flavonoids that have been largely overlooked despite anti-inflammatory properties, and this is among the first studies to test it in a neurodevelopmental disorder model.

Questions still open

  • What is the mechanism by which cannflavin B normalizes neuronal oscillations? Would chronic treatment maintain these effects? Could cannflavin B be combined with behavioral therapies for greater effect?

Common questions

What is cannflavin B?
It is a non-psychoactive flavonoid naturally found in the cannabis plant. Unlike THC, it does not produce a high, and unlike CBD, it belongs to a different class of compounds (flavonoids) with distinct anti-inflammatory properties.
Could this help with autism?
In this rat model, cannflavin B improved social behavior and corrected brain wave abnormalities associated with autism-like features. However, animal models have limited relevance to human autism, and no clinical data exists yet.

Read the original research

Cannflavin B ameliorates behavioural and neuronal systems alterations in adolescent rats exposed to prenatal valproic acid.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 195, 118949

Citation

Williams, Olivia O F; Coppolino, Madeleine; Manduca, Joshua D; Demers, Taylor C; Henry-Duru, Paula T; Mueller, Talen C; Soubeyrand, Eric; Perrin, Colby J; Akhtar, Tariq A; Perreault, Melissa L. (2026). Cannflavin B ameliorates behavioural and neuronal systems alterations in adolescent rats exposed to prenatal valproic acid.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 195, 118949. https://doi.org/10.1016/j.biopha.2025.118949

Explore the wider topic